SPOTLIGHT: Wockhardt lining up $800M for Alpharma bid?

The Economic Times is reporting that India's Wockhardt is lining up $800 million to buy US generic drug company Alpharma. Alpharma announced last week that it is considering alternative strategies. Another potential suitor could be India's Ranbaxy, another major generic drug company. Story

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.